Let’s Get Started
There are several options that may help you afford your Genentech medicine. Answer a few simple questions to find out which one might be right for you.
Do you have health insurance?
Do you have commercial health insurance?What does this mean?
Have you been prescribed ACTEMRA Subcutaneous (SC)?What does this mean?
Have you been prescribed ACTEMRA Intravenous (IV)?What does this mean?
Do you have a Medicare Advantage Plan with prescription coverage or a Medicare Part D Plan?
Are you already getting financial assistance to help pay for your medicine?What does this mean?
Are you taking ACTEMRA for an FDA-approved use?
You Might Qualify for a Referral to the ACTEMRA Co-pay Card Program
Genentech Rheumatology Access Solutions can refer you to the ACTEMRA Co-pay Card Program. It can help you with the out-of-pocket costs of your Genentech medicine, if you’re eligible.*
*In order to be eligible for the ACTEMRA Co-pay Card Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit RACopay.com for the full list of terms and conditions.
You Might Qualify for a Referral to an Independent Co-pay Assistance Foundation
If you need help with your co-pay for your Genentech medicine, we can refer you to an independent co-pay assistance foundation.*
*Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.
You Might Qualify for a Referral to the Genentech® Access to Care Foundation, or GATCF
GATCF can help you receive your Genentech medicine free of charge, if you qualify.*
*If you have health insurance, you must have already tried other types of patient assistance to qualify for free Genentech medicine from GATCF. This includes the ACTEMRA Co-pay Card Program and support from independent co-pay assistance foundations. You must also meet financial criteria. If you do not have insurance, you must meet different financial criteria.
Please Contact Us
Please call (866) 422-2377 for assistance.
You Might Qualify for Extra Help From Medicare*
You may qualify for Extra Help from Medicare to help cover the costs of your Medicare prescriptions.
*This program is provided by Medicare. For more information or to find out if you qualify, contact Social Security. Call (800) 772-1213 or visit SocialSecurity.gov/extrahelp.
Important Safety Information & Indication
What it Treats
ACTEMRA® (tocilizumab) is a prescription medicine used to treat:
- Adults with moderately to severely active rheumatoid arthritis, or RA. ACTEMRA is used after at least one other medicine called a Disease Modifying Anti-Rheumatic Drug (DMARD) has been used and did not work well.
- Adults with giant cell arteritis (GCA).
- People with active polyarticular juvenile idiopathic arthritis (PJIA) age 2 years and above.
- People with active systemic juvenile idiopathic arthritis (SJIA) age 2 years and above.
- People who experience severe or life-threatening CRS following chimeric antigen receptor T cell treatment age 2 years and above.
ACTEMRA is not approved for subcutaneous use in people with SJIA or CRS.
It is not known if ACTEMRA is safe and effective in children with PJIA or SJIA under 2 years of age, in children with CRS under 2 years of age, or in children with conditions other than PJIA, SJIA or CRS.
Important Safety Information
ACTEMRA can cause serious side effects. ACTEMRA changes the way a patient’s immune system works. This can make a patient more likely to get infections or make any current infection worse. Some patients have serious infections while taking ACTEMRA, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some patients taking ACTEMRA have died from these infections.
ACTEMRA can cause other serious side effects. These include:
- Stomach tears
- Changes in blood test results, including low neutrophil (white blood cells) and platelet (platelets help the blood to clot) counts, and increases in certain liver function test levels and blood cholesterol levels
- An increased risk of certain cancers by changing the way a patient’s immune system works
- Hepatitis b infection in people who carry the virus in their blood
- Serious allergic reactions, including death. These may happen with ACTEMRA infusions or injections, even if they did not occur with an earlier infusion or injection. If a patient has had hives, a rash, or experienced flushing after injecting, the patient should tell their doctor or nurse before their next injection
- Nervous system problems
ACTEMRA affects the immune system and may increase a patient’s risk of certain cancers.
Most common side effects in patients treated with ACTEMRA:
Patients must tell their doctor if they have these or any other side effect that bothers them or does not go away:
- Upper respiratory tract infections (like common cold and sinus infections)
- Increased blood pressure (also called hypertension)
- Injection site reactions (for subcutaneous use only)
ACTEMRA & pregnancy:
Patients must tell their doctor if they are planning to become pregnant, are pregnant, plan to breast-feed, or are breast-feeding. The patient and their doctor should decide if the patient will take ACTEMRA or breast-feed. Patients should not do both. If a patient is pregnant and taking ACTEMRA, they must join the pregnancy registry. To learn more, patients should call 1-877-311-8972 or talk to their doctor to register.
Patients must tell their doctor right away if they are experiencing any side effects.
Report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Call Genentech at 1-888-835-2555.
Please see the full Prescribing Information, including BOXED WARNING and Medication Guide, for additional Important Safety Information.